PD-1 / PD-L1 Antibodies

Cat. No.

AT0014

CAS No.

2639481-06-2

Lipustobart

Lipustobart is a humanized IgG4κ monoclonal antibody directed against PD-1 (programmed cell death protein 1 / CD279), a key immune checkpoint receptor involved in T cell regulation. By blocking PD-1 signaling, Lipustobart restores T cell activity and promotes antitumor immune responses. This antibody is suitable for research in cancer immunotherapy, immune checkpoint blockade, and T cell exhaustion.

Cat. No.

AT0031

CAS No.

2329669-72-7

Vudalimab

Vudalimab is a fully human bispecific monoclonal antibody targeting both PD-1 and CTLA-4, two key immune checkpoint receptors. By simultaneously blocking these pathways, Vudalimab enhances T-cell activation in the tumor microenvironment and is widely used in research on immune checkpoint blockade, tumor immunology, and combination immunotherapy strategies.

Cat. No.

AT0040

CAS No.

2350298-85-8

Finotonlimab

Synonyms: SCT-I10A

Finotonlimab (SCT-I10A) is a recombinant humanized IgG monoclonal antibody targeting PD-1, a critical immune checkpoint molecule. By blocking PD-1 signaling, Finotonlimab restores T cell activity and is applicable in research on solid tumors, lymphomas, and immune checkpoint inhibitor development.

Cat. No.

AT0041

CAS No.

1858168-59-8

Tislelizumab

Tislelizumab is a humanized monoclonal antibody that binds to the PD-1 receptor, effectively blocking its interaction with the ligands PD-L1 and PD-L2. By reactivating exhausted T cells, Tislelizumab enhances antitumor immunity. It is widely used in immuno-oncology research, including studies on Hodgkin’s lymphoma, urothelial carcinoma, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma.

Cat. No.

AT0056

CAS No.

2417649-97-7

Tagitanlimab

Synonyms: HBM-9167; KL-A167

Tagitanlimab (HBM-9167) is a humanized monoclonal antibody of the IgG1κ isotype, designed to selectively inhibit the interaction between programmed death-ligand 1 (PD-L1) and its receptor PD-1. This interaction blockade is pivotal in modulating the immune system's response to tumor cells, potentially enhancing anti-tumor activity. Tagitanlimab is primarily investigated for its therapeutic potential in the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), positioning it as a significant candidate for oncology research.

Cat. No.

AT0060

CAS No.

1808081-43-7

Gilvetmab

Gilvetmab is a caninized anti-PD-1 monoclonal antibody designed to exhibit potent inhibitory effects on the PD-1/PD-L1 interaction. By blocking this pathway, Gilvetmab effectively disrupts a critical immune checkpoint mechanism, thereby enhancing T-cell function and immune response against tumor cells. This antibody is specifically tailored for use in research related to malignant melanoma, providing a valuable tool for investigating the role of the PD-1/PD-L1 pathway in cancer immunotherapy.

Cat. No.

AT0096

CAS No.

2148321-77-9

Balstilimab

Synonyms: AGEN2034

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody designed to selectively target and inhibit the programmed cell death protein 1 (PD-1). This interaction is intended to enhance the body's immune response against various cancers by blocking the PD-1 pathway, which is often exploited by tumors to evade immune detection.

Cat. No.

AT0132

CAS No.

2342597-81-1

Garivulimab

Synonyms: BGB-A333

Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody engineered to specifically target and bind to the programmed death-ligand 1 (PD-L1). This antibody selectively inhibits the interaction between PD-L1 and its receptor, programmed death-1 (PD-1), a critical pathway exploited by tumors to evade immune detection. Through this mechanism, Garivulimab exhibits potent antitumor activity, making it a valuable tool for cancer immunotherapy research.

Cat. No.

AT0198

CAS No.

2245725-04-4

Tebotelimab

Synonyms: MGD-013

Tebotelimab (MGD-013) is a humanized IgG4κ bispecific antibody designed for dual affinity re-targeting (DART) of PD-1 and LAG-3. This therapeutic agent demonstrates high affinity binding to cell-surface expressed PD-1 and LAG-3, with half-maximal effective concentrations (EC50s) of 1.65 nM and 0.41 nM in NS0 cells, respectively. By effectively blocking the interactions between PD-1/PD-L1, PD-1/PD-L2, and LAG-3/HLA (MHC-II), as well as inhibiting PD-1 signaling pathways, Tebotelimab plays a crucial role in restoring the function of exhausted T-cells. This restoration is pivotal in enhancing anti-tumor immunity, making Tebotelimab a significant tool in cancer immunotherapy research.

Cat. No.

AT0250

CAS No.

2259860-24-5

Zimberelimab

Synonyms: GLS-010; AB-122; WBP-3055

Zimberelimab (GLS-010) is a fully human monoclonal antibody of the IgG4 subclass that targets PD-1 with a high affinity, demonstrated by an EC50 of 210 pM. This antibody effectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2, with IC50 values of 580 pM and 670 pM respectively, in CHO-S cell assays. Zimberelimab has been shown to exhibit potent antitumor activities. It is applicable in the research of various cancers, including cervical cancer, non-small cell lung cancer, and classical Hodgkin’s lymphoma, making it a valuable tool for oncological studies focused on immune checkpoint pathways.

Cat. No.

AT0282

CAS No.

1036730-42-3

Pidilizumab

Synonyms: CT-011; MDV9300

Pidilizumab (CT-011) is a humanized IgG1k monoclonal antibody targeting PD-1. It functions as a DLL1 antagonist, offering significant potential for research into hematologic malignancies. This antibody is designed for specificity to PD-1, making it a valuable tool for studies focused on immune checkpoint pathways and their roles in cancer immunotherapy.

Cat. No.

AT0285

CAS No.

1428935-60-7

Durvalumab

Synonyms: MEDI 4736

Durvalumab (MEDI4736) is a human monoclonal antibody targeting PD-L1. This antibody effectively inhibits the interaction of PD-L1 with its receptors PD-1 and CD80, demonstrating inhibitory concentrations (IC50) of 0.1 nM and 0.04 nM, respectively. Durvalumab's high specificity and potent binding affinity make it a valuable tool for research into checkpoint inhibition and immune response modulation.

Cat. No.

AT0372

CAS No.

2249882-54-8

Ezabenlimab

Synonyms: BI-754091

Ezabenlimab (BI-754091) is a monoclonal antibody targeting the programmed death-1 (PD-1) receptor, exhibiting a binding affinity with a dissociation constant (Kd) of 6 nM, as determined in CHO cell assays. This antibody effectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby enhancing interferon-γ secretion in T cells. The blockade of this pathway by Ezabenlimab has demonstrated the ability to inhibit tumor growth in vivo, highlighting its potential utility in oncological research and therapeutic applications.

Cat. No.

AT0469

CAS No.

946414-94-4

Nivolumab

Synonyms: BMS-936558; ONO-4538; MDX-1106

Nivolumab is a human IgG4 monoclonal antibody that inhibits the programmed death receptor-1 (PD-1) pathway, offering therapeutic benefits in the management of advanced (metastatic) non-small cell lung cancer. This antibody functions by blocking the interaction between PD-1 and its ligands, thereby enhancing the immune response against tumor cells. It is specifically designed for the treatment of patients with advanced stages of this malignancy, where it has shown efficacy in improving patient outcomes.

Cat. No.

AT0598

CAS No.

1924598-82-2

Toripalimab

Toripalimab is a selective, recombinant, humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. This antibody binds specifically to PD-1, effectively blocking its interaction with PD-L1 and PD-L2 ligands. Through this mechanism, Toripalimab disrupts the PD-1 mediated signaling pathway, which is critical in regulating the immune system's response to cancer cells. Clinically, Toripalimab has demonstrated significant anti-tumor activity across a range of malignancies, including melanoma, lung cancer, various digestive tract tumors, hepatobiliary and pancreatic cancers, neuroendocrine tumors, nasopharyngeal carcinoma, and urothelial carcinoma. This antibody is pivotal in research focused on immunotherapy and the immune evasion strategies of tumors.

Cat. No.

AT0856

CAS No.

2102192-68-5

Envafolimab

Synonyms: ASC 22; KN 035

Envafolimab (ASC 22; KN 035) is a recombinant fusion protein comprising a humanized single-domain anti-PD-L1 antibody linked to the Fc fragment of a human IgG1 antibody. This biologic is designed to inhibit the interaction between PD-L1 and PD-1, exhibiting an IC50 value of 5.25 nM, indicative of its potent inhibitory activity. Envafolimab is primarily utilized in research focused on solid tumors, providing a valuable tool for investigating the therapeutic potential of PD-L1 blockade in oncology.

Cat. No.

AT0982

CAS No.

1801342-60-8

Cemiplimab

Cemiplimab, a monoclonal IgG4 antibody, exhibits high affinity for the programmed death receptor-1 (PD-1). It effectively blocks the PD-1/PD-L1 interaction, which is critical in mediating T-cell suppression. This antibody is predominantly utilized in the study of squamous cell carcinoma of the skin, providing a valuable tool for investigating immune checkpoint blockade therapies in cancer research.

Cat. No.

AT1027

CAS No.

2416595-46-3

Lorigerlimab

Synonyms: MGD019

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART) designed to simultaneously inhibit the activity of PD-1 and CTLA-4 immune checkpoints. By blocking these pathways, Lorigerlimab enhances T-cell mediated immune responses, which are critical in the control and elimination of tumors. This antibody is particularly relevant for studies focused on metastatic castration-resistant prostate cancer (mCRPC), providing a valuable tool for research in immune checkpoint blockade therapies and their role in cancer immunology.

Cat. No.

AT1112

CAS No.

2022215-59-2

Dostarlimab

Synonyms: TSR-042

Dostarlimab (TSR-042) is a humanized monoclonal antibody targeting PD-1 (Programmed Death-1). This antibody exhibits high affinity binding to PD-1, effectively blocking its interaction with the ligands PD-L1 and PD-L2. The inhibition constants (IC50) are determined to be 1.8 nM for PD-L1 and 1.5 nM for PD-L2, respectively. Dostarlimab serves as a potent inhibitor in the modulation of immune responses, making it a valuable tool in immunotherapy research.

Cat. No.

AT1214

CAS No.

2098225-93-3

Budigalimab

Synonyms: ABBV 181; PR 1648817

Budigalimab (ABBV 181; PR 1648817) is a humanized recombinant IgG1 monoclonal antibody specifically designed to target the programmed cell death 1 (PD-1) receptor. This antibody features a modified Fc region with a mutation that diminishes Fc receptor interactions and effector function inhibition. By effectively blocking the interaction between PD-1 and its ligand PD-L1, Budigalimab exhibits potent anti-tumor activity. It is primarily utilized in research focused on various solid tumors, providing a valuable tool for oncology studies.

Cat. No.

AT1355

Pembrolizumab (anti-PD-1)

Synonyms: MK-3475 (anti-PD-1; Lambrolizumab (anti-PD-1

Pembrolizumab is a humanized IgG4 monoclonal antibody that functions as a programmed death-1 (PD-1) inhibitor. It effectively blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This inhibition prevents the suppression of T-cell activity, typically mediated by PD-1 signaling in cells expressing these ligands, thereby enhancing the immune response against tumor cells. Pembrolizumab is utilized extensively in immunotherapy protocols for various cancers, leveraging its ability to modulate immune system responses.

Cat. No.

AT1362

CAS No.

3002062-67-8

Abazistobart

Abazistobart is a chimeric and humanized monoclonal antibody designed to act as both an immunostimulant and an antineoplastic agent. It specifically targets the programmed cell death protein 1 (PDCD1), effectively blocking its signaling pathway. This blockade results in the activation of the immune system and exhibits antineoplastic activity, making Abazistobart a valuable tool in cancer research.